AlphaFold predicted structure
HGSNAT · Q68CP4

Mean pLDDT
79.9/ 100
Confident
663 residues
Confidence breakdown
- Very high(≥ 90)49%
- Confident(70–90)28%
- Low(50–70)7%
- Very low(< 50)16%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
heparan-alpha-glucosaminide N-acetyltransferase
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalLysosomal storage disorder
BIALLELIC, autosomal or pseudoautosomalMucopolysaccharideosis, Gaucher, Fabry
BIALLELIC, autosomal or pseudoautosomalRetinal disorders
BIALLELIC, autosomal or pseudoautosomalSkeletal dysplasia
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomal+4 more panels — install the extension to see the full list inline on any page.
mucopolysaccharidosis type 3C
retinitis pigmentosa 73
mucopolysaccharidosis type 3
retinitis pigmentosa
Retinal dystrophy
neurodegenerative disease
hereditary disease
inherited retinal dystrophy
synovial plica syndrome
retinal disorder
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Heparan-alpha-glucosaminide N-acetyltransferase
Lysosomal acetyltransferase that acetylates the non-reducing terminal alpha-glucosamine residue of intralysosomal heparin or heparan sulfate, converting it into a substrate for luminal alpha-N-acetyl glucosaminidase
HGSNAT · Q68CP4

Mean pLDDT
79.9/ 100
Confident
663 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0